Results 151 to 160 of about 67,365 (299)

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection. [PDF]

ACG Case Rep J
Singh N, Chaparro E, Shapiro JM, Husu EN.   +3 more
europepmc   +1 more source

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice

, 2017
Leena Liljedahl, Jenny Norlin, James N. McGuire, Peter James   +3 more
openalex   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. [PDF]

Diabetes Ther
Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Patients with Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-like Peptide-1 Receptor Agonist Therapy

Ezan Chaudhry, Payal Kakadiya, Hayden Vaughn, Simon Gray, Jonathan J. Hansen, John P. Haydek, Animesh Jain, Millie D. Long, Hans Herfarth, Edward L. Barnes   +9 more
openalex   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity. [PDF]

Hypertens Res
Koyanagi Y, Iigaya K, Ikeda K, Onimaru H, Izumizaki M.   +4 more
europepmc   +1 more source

Long‐Term Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes

Akiva Rosenzveig, Leben Tefera, Ankit Agrawal, Judah Rajendran, Faysal Massad, Osamah Badwan, Julia Wajsberg, Pulkit Chaudhury, David A. Zidar, Timir K. Paul, Deepak L. Bhatt, Aravinda Nanjundappa   +11 more
openalex   +1 more source

Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery

VIEW, EarlyView.
This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf, Salman Farsi Taharat, Md. Sadek Miah, Hasan Tasnim Salehin, M. Azam Ali, Shoeb Ahmed   +5 more
wiley   +1 more source